Novoprotein(SH:688137) Zheng Quan Zhi Xing·2025-08-27 11:24Core Viewpoint - The company plans to use part of the excess raised funds, amounting to 72 million RMB, to permanently supplement its working capital, which aligns with its business development needs and aims to enhance profitability while protecting shareholder interests [3][5]. Fundraising Overview - The company successfully completed its initial public offering (IPO) on September 26, 2022, raising a total of 1,742.1958 million RMB, with a total excess of 242.1958 million RMB after deducting issuance costs [1][2]. - The total investment amount for the core diagnostic raw materials and innovative diagnostic reagents industrialization project is 1,500 million RMB, which will utilize the raised funds [2]. Use of Excess Funds - The company intends to allocate 72 million RMB, which is 29.73% of the total excess funds, to permanently supplement working capital, ensuring that the funding needs for investment projects are met [3][4]. - The cumulative use of excess funds for working capital will not exceed 30% of the total excess funds within the last 12 months, complying with regulatory requirements [4]. Impact on Daily Operations and Commitments - The company commits that the use of excess funds will not affect the funding needs of investment projects and will refrain from high-risk investments or providing financial assistance to entities outside its controlling subsidiaries within the next 12 months [4][5]. - The supervisory board supports the decision, stating that it meets regulatory requirements and does not harm the interests of shareholders, particularly minority shareholders [5]. Review Process and Opinions - The proposal to use part of the excess funds was approved in nine meetings and will be submitted for shareholder approval [5]. - The sponsor institution has verified that the use of excess funds for working capital will enhance efficiency and reduce financial costs without affecting the normal progress of investment projects [5].